Tags

Type your tag names separated by a space and hit enter

Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China.
J Clin Microbiol. 2008 Apr; 46(4):1317-21.JC

Abstract

The aim of this study was to investigate the prevalences of plasmid-mediated AmpC beta-lactamases (PABLs) in isolates of Escherichia coli and Klebsiella spp. from a university hospital in China. A total of 1,935 consecutive nonrepeat clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca were collected between January 2003 and July 2005. The isolates with cefoxitin zone diameters less than 18 mm (screen positive) were selected for PCR of the bla(AmpC) genes and sequencing. Fifty-four (2.79%) isolates harbored PABLs, as demonstrated by PCR and isoelectric focusing. Sequence analysis revealed the presence of bla(DHA-1) and bla(CMY-2) genes. The Southern blot hybridization studies confirmed that bla(CMY-2) and bla(DHA-1) were located on plasmids. Based on species, PABLs were detected in 4.29% (29 isolates of DHA-1 and 1 isolate of CMY-2) of K. pneumoniae, 1.91% (11 isolates of DHA-1 and 12 isolates of CMY-2) of E. coli, and 3.03% (1 isolate of DHA-1) of K. oxytoca isolates. In contrast to our anticipation, the occurrence rate of DHA-1-producing K. pneumonia significantly decreased (P < 0.01), from 7.54% in 2003 to 2.72% in 2004. The results of random amplified polymorphic DNA analysis indicate that the prevalences of DHA-1-producing K. pneumoniae and CMY-2-producing E. coli strains were not due to epidemic strains. In conclusion, DHA-1 was the most prevalent acquired AmpC beta-lactamase in this collection of isolates from a medical center in China, and DHA-1-producing K. pneumoniae was the most prevalent bacterium harboring a PABL. To the best of our knowledge, this is the first report of CMY-2-type AmpC beta-lactamases in the Chinese mainland.

Authors+Show Affiliations

Department of Clinical Laboratory Medicine, Sixth Affiliate Hospital of Shanghai Jiao Tong University, 600 Yi Shan Rd., Shanghai 200233, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18305137

Citation

Li, Yi, et al. "Prevalence of Plasmid-mediated AmpC Beta-lactamases in a Chinese University Hospital From 2003 to 2005: First Report of CMY-2-Type AmpC Beta-lactamase Resistance in China." Journal of Clinical Microbiology, vol. 46, no. 4, 2008, pp. 1317-21.
Li Y, Li Q, Du Y, et al. Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China. J Clin Microbiol. 2008;46(4):1317-21.
Li, Y., Li, Q., Du, Y., Jiang, X., Tang, J., Wang, J., Li, G., & Jiang, Y. (2008). Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China. Journal of Clinical Microbiology, 46(4), 1317-21. https://doi.org/10.1128/JCM.00073-07
Li Y, et al. Prevalence of Plasmid-mediated AmpC Beta-lactamases in a Chinese University Hospital From 2003 to 2005: First Report of CMY-2-Type AmpC Beta-lactamase Resistance in China. J Clin Microbiol. 2008;46(4):1317-21. PubMed PMID: 18305137.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of plasmid-mediated AmpC beta-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-Type AmpC beta-lactamase resistance in China. AU - Li,Yi, AU - Li,Qing, AU - Du,Yuzhen, AU - Jiang,Xiaofei, AU - Tang,Jin, AU - Wang,Jianqiang, AU - Li,Guilan, AU - Jiang,Yanqun, Y1 - 2008/02/27/ PY - 2008/2/29/pubmed PY - 2008/4/23/medline PY - 2008/2/29/entrez SP - 1317 EP - 21 JF - Journal of clinical microbiology JO - J Clin Microbiol VL - 46 IS - 4 N2 - The aim of this study was to investigate the prevalences of plasmid-mediated AmpC beta-lactamases (PABLs) in isolates of Escherichia coli and Klebsiella spp. from a university hospital in China. A total of 1,935 consecutive nonrepeat clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca were collected between January 2003 and July 2005. The isolates with cefoxitin zone diameters less than 18 mm (screen positive) were selected for PCR of the bla(AmpC) genes and sequencing. Fifty-four (2.79%) isolates harbored PABLs, as demonstrated by PCR and isoelectric focusing. Sequence analysis revealed the presence of bla(DHA-1) and bla(CMY-2) genes. The Southern blot hybridization studies confirmed that bla(CMY-2) and bla(DHA-1) were located on plasmids. Based on species, PABLs were detected in 4.29% (29 isolates of DHA-1 and 1 isolate of CMY-2) of K. pneumoniae, 1.91% (11 isolates of DHA-1 and 12 isolates of CMY-2) of E. coli, and 3.03% (1 isolate of DHA-1) of K. oxytoca isolates. In contrast to our anticipation, the occurrence rate of DHA-1-producing K. pneumonia significantly decreased (P < 0.01), from 7.54% in 2003 to 2.72% in 2004. The results of random amplified polymorphic DNA analysis indicate that the prevalences of DHA-1-producing K. pneumoniae and CMY-2-producing E. coli strains were not due to epidemic strains. In conclusion, DHA-1 was the most prevalent acquired AmpC beta-lactamase in this collection of isolates from a medical center in China, and DHA-1-producing K. pneumoniae was the most prevalent bacterium harboring a PABL. To the best of our knowledge, this is the first report of CMY-2-type AmpC beta-lactamases in the Chinese mainland. SN - 1098-660X UR - https://www.unboundmedicine.com/medline/citation/18305137/Prevalence_of_plasmid_mediated_AmpC_beta_lactamases_in_a_Chinese_university_hospital_from_2003_to_2005:_first_report_of_CMY_2_Type_AmpC_beta_lactamase_resistance_in_China_ L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&amp;pmid=18305137 DB - PRIME DP - Unbound Medicine ER -